• Chronic Hepatitis
    • Stefan S Zeuzem
    • Stefan S Zeuzem: Influence Statistics

      Stefan S Zeuzem

      Stefan S Zeuzem

      Show email address

      Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany;, maximilian.kinzler@kgu.de, (M.N.K.);, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Stefan S Zeuzem:Expert Impact

      Concepts for whichStefan S Zeuzemhas direct influence:Chronic hepatitis,Hcv genotype,Hepatitis virus,Liver fibrosis,Patients chronic hepatitis,Antiviral therapy,Hepatocellular carcinoma,Liver cirrhosis.

      Stefan S Zeuzem:KOL impact

      Concepts related to the work of other authors for whichfor which Stefan S Zeuzem has influence:Hepatocellular carcinoma,Chronic hepatitis,Liver fibrosis,Hcv infection,Antiviral therapy,Pegylated interferon,Hcc patients.

      KOL Resume for Stefan S Zeuzem


      Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany;, (M.N.K.);, (C.K.);, (J.T.);, (S.Z.)

      Medizinische Klinik I, Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland


      Department of Internal Medicine 1, Goethe-University Hospital Frankfurt, Frankfurt, Germany


      Department of Internal Medicine, Goethe University Hospital Frankfurt, Frankfurt, Germany.

      Johann Wolfgang Goethe University Medical Center, Frankfurt/Main, Germany

      Universitätsklinikum Frankfurt, Medizinische Klinik 1


      Department of Internal Medicine 1, Goethe‐University Hospital Frankfurt, Frankfurt, Germany

      Medizinische Klinik I, Universit?tsklinikum Frankfurt, Frankfurt

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Stefan S Zeuzem is among the top experts in the world.
      Concept World rank
      2b study #1
      eot fu144 #1
      hcv‐associated cirrhosis #1
      mirna26b expression patients #1
      histologic steatosis mrspectroscopy #1
      genotype ras prevalence #1
      hcv p7 responders #1
      patients active regimen #1
      pegifnα2a albifn #1
      pegylated interferon‐α2a #1
      impact fibrosis #1
      diagnosis liver cirrhosis #1
      nuclear transport hmlh1 #1
      prk2 interaction #1
      hbsag viral genomes #1
      localized displacements #1
      irgd leverages #1
      outcomes telbivudine treatment #1
      male polyethylene #1
      chc chc hcc #1
      svr baseline ip10 #1
      prevalence urban donors #1
      cd15 expression cd15 #1
      treated 24 #1
      sustained viral eradication #1
      dose peginterferon ribavirin #1
      ribavirin concentrations anaemia #1
      ascites‐mobilizing pump #1
      hcv #1
      infection background #1
      zeitalter direkt #1
      liver cirrhosis chronic #1
      telaprevir drug #1
      treatment duration treatment #1
      itpadeficient #1
      hmutlbeta #1
      viral kinetics patients #1
      pglu605del #1
      factors svr12 #1
      sprint1studie #1
      chronic humans mutation #1
      genotypes 1 5 #1
      proteins antiviral #1
      interferonα telaprevir #1
      liver stiffness lte #1
      patients bot 05 #1
      detectable resistance mutations #1
      rab3ad #1
      itmn191 rg7227 #1
      highdose ppi #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Stefan S Zeuzem

      KOL-Index: 24489

      BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial data for treatment remain limited. We assessed the combination of two direct-acting antivirals, ombitasvir (NS5A inhibitor) and paritaprevir (NS3/4A protease inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV ...

      Known for 4 Infection | Patients Hcv Genotype | Ritonavir Ribavirin | 12 Weeks | Treatment Week
      KOL-Index: 24011

      BACKGROUND: Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone.

      METHODS: We conducted a randomized trial in which 31 patients with HDV infection received treatment with 180 μg of peginterferon alfa-2a ...

      Known for Hdv Rna | Adefovir Peginterferon | Hepatitis Delta | 48 Weeks | Polyethylene Glycols
      KOL-Index: 23914

      BACKGROUND: New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these ...

      Known for Grazoprevir Ruzasvir | 100 Day | Chronic Heterocyclic Compounds | 12 Weeks | Uprifosbuvir 450
      KOL-Index: 22852

      BACKGROUND: Only 15-20% of patients with chronic hepatitis C achieve a sustained virological response with interferon therapy. The aim of this study was to compare the efficacy and safety of interferon alpha2b in combination with oral ribavirin with interferon alone, for treatment of chronic infection with hepatitis C virus (HCV).

      METHODS: 832 patients aged 18 years or more with chronic HCV who had not been treated with interferon or ribavirin, were enrolled and randomly allocated one of ...

      Known for 48 Weeks | Interferon Α2b | Randomised Trial | Combination Regimen | Patients Chronic Hepatitis
      KOL-Index: 20600

      BACKGROUND: In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment.

      METHODS: A total of 334 patients who had chronic infection with HCV genotype 1 and had not been treated previously were randomly assigned to receive one of four treatments ...

      Known for Peginterferon Ribavirin | Chronic Hcv | 12 Weeks | Sustained Virologic Response | Pr48 Rate
      KOL-Index: 20275

      BACKGROUND: The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies. We aimed to assess the efficacy and safety of 12 weeks of coformulated glecaprevir and pibrentasvir in patients with hepatitis C virus (HCV) infection and compensated cirrhosis.

      METHODS: We did this single-arm, open-label, multicentre phase 3 study at 40 sites in Belgium, ...

      Known for Compensated Cirrhosis | 6 Infection | Genotype 1 | Pibrentasvir Patients | Phase 3
      KOL-Index: 20162

      BACKGROUND: We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated. We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.

      METHODS: We did this randomised, double-blind, phase 3 trial at 169 investigational sites in 24 ...

      Known for Simeprevir Telaprevir | Genotype 1 | Peginterferon Ribavirin | Chronic Hepatitis | Phase 3
      KOL-Index: 19585

      BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin.

      METHODS: We randomly assigned 1469 patients with HCV genotype 2 or 3 to receive 180 ...

      Known for 24 Weeks | Hcv Genotype | Peginterferon Ribavirin | 2 3 Treatment | Virologic Response
      KOL-Index: 19391

      BACKGROUND: Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week and 12-week courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection.

      METHODS: We conducted two phase 3, randomized, open-label, multicenter trials. Patients with genotype 1 infection were randomly ...

      Known for 12 Weeks | Hcv Genotype | 3 Infection | Pibrentasvir Patients | Sustained Virologic Response
      KOL-Index: 19073

      BACKGROUND & AIMS: Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection. We performed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon-α2a (PegIFN), and ribavirin (RBV) in patients with HCV genotype-1 infection previously treated with PegIFN and RBV.

      METHODS: We analyzed data from patients who did not respond (null ...

      Known for Pegifn Rbv | Patients Simeprevir | Sustained Virologic Response | Phase Iib | 24 Weeks
      KOL-Index: 18699

      Cholecystokinin (CCK) and related peptides are potent growth factors in the gastrointestinal tract and may be important for human cancer. CCK exerts its growth modulatory effects through G(q)-coupled receptors (CCK(A) and CCK(B)) and activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2). In the present study, we investigated the different mechanisms participating in CCK-induced activation of ERK1/2 in pancreatic AR42J cells expressing both CCK(A) and CCK(B). CCK ...

      Known for Protein Kinase | Erk1 2 | Egfr Ras | Epidermal Growth Factor | Extracellular Signal
      KOL-Index: 18452

      BACKGROUND & AIMS: To maximize sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, treatment with pegylated interferon and ribavirin has been genotype-specific (1 vs non-1). We evaluated the effects of ribavirin and peginterferon alfa-2a dose reductions on SVR in patients infected with HCV genotype 1.

      METHODS: Data were pooled from 569 patients enrolled in 2 phase III trials of 48 weeks of treatment with peginterferon alfa-2a and ribavirin. All ...

      Known for Ribavirin Dose | Svr Patients | Treatment Peginterferon | Genotype 1 | Phase Iii
      KOL-Index: 18309

      In PC12 cells, a well studied model for neuronal differentiation, an elevation in the intracellular cAMP level increases cell survival, stimulates neurite outgrowth, and causes activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2). Here we show that an increase in the intracellular cAMP concentration induces tyrosine phosphorylation of two receptor tyrosine kinases, i.e. the epidermal growth factor (EGF) receptor and the high affinity receptor for nerve growth ...

      Known for Neurite Outgrowth | Pc12 Cells | Growth Factor | Erk1 2 | Map Kinase

      Key People For Chronic Hepatitis

      Top KOLs in the world
      Patrick Marcellin
      chronic hepatitis adefovir dipivoxil hcv genotype
      Michael Peter Manns
      chronic hepatitis liver transplantation hepatocellular carcinoma
      Anna Shuk‐Fong Lok
      chronic hepatitis hepatocellular carcinoma united states
      Stefan S Zeuzem
      chronic hepatitis hcv genotype liver fibrosis
      Jay H Hoofnagle¶¶
      chronic hepatitis liver injury united states
      Zachary D Goodman
      chronic hepatitis liver fibrosis hepatocellular carcinoma

      Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany;, maximilian.kinzler@kgu.de, (M.N.K.);, christina.klasen@t-online.de, (C.K.);, joerg.trojan@kgu.de, (J.T.);, stefan.zeuzem

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.